Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
---|---|---|---|---|---|---|---|---|
2024-10-08 | ALNYLAM PHARMACEUTICALS, INC. | Garg Pushkal
(CMO & EVP Dev & Med Affairs) |
A | Common Stock | A | 96 | $0.00 - $0.00 | $0 |
2024-08-20 | ALNYLAM PHARMACEUTICALS, INC. | Greenstreet Yvonne
(Chief Executive Officer) |
S | Common Stock | D | 15000 | $280.00 - $280.00 | $4,200,000 |
2024-08-20 | ALNYLAM PHARMACEUTICALS, INC. | Greenstreet Yvonne
(Chief Executive Officer) |
M | Common Stock | A | 15000 | $85.00 - $85.00 | $1,275,000 |
2024-08-01 | ALNYLAM PHARMACEUTICALS, INC. | Greenstreet Yvonne
(Chief Executive Officer) |
S | Common Stock | D | 15148 | $270.00 - $270.00 | $4,089,960 |
2024-08-01 | ALNYLAM PHARMACEUTICALS, INC. | Greenstreet Yvonne
(Chief Executive Officer) |
M | Common Stock | A | 15148 | $85.00 - $85.00 | $1,287,580 |
2024-07-11 | ALNYLAM PHARMACEUTICALS, INC. | Greenstreet Yvonne
(Chief Executive Officer) |
S | Common Stock | D | 7093 | $261.00 - $261.00 | $1,851,273 |
2024-06-24 | ALNYLAM PHARMACEUTICALS, INC. | PYOTT DAVID E I
(Director) |
S | Common Stock | D | 32450 | $220.00 - $222.00 | $7,161,360 |
2024-06-24 | ALNYLAM PHARMACEUTICALS, INC. | PYOTT DAVID E I
(Director) |
M | Common Stock | A | 32450 | $70.20 - $88.95 | $2,620,611 |
2024-06-25 | ALNYLAM PHARMACEUTICALS, INC. | Garg Pushkal
(CMO & EVP Dev & Med Affairs) |
S | Common Stock | D | 2103 | $221.71 - $235.19 | $485,767 |
2024-06-24 | ALNYLAM PHARMACEUTICALS, INC. | Garg Pushkal
(CMO & EVP Dev & Med Affairs) |
A | Common Stock | A | 4295 | $0.00 - $0.00 | $0 |
2024-06-25 | ALNYLAM PHARMACEUTICALS, INC. | Greenstreet Yvonne
(Chief Executive Officer) |
S | Common Stock | D | 8301 | $221.71 - $235.19 | $1,917,469 |
2024-06-24 | ALNYLAM PHARMACEUTICALS, INC. | Greenstreet Yvonne
(Chief Executive Officer) |
A | Common Stock | A | 16953 | $0.00 - $0.00 | $0 |
2024-06-25 | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V.
(EVP, Chief Financial Officer) |
S | Common Stock | D | 1605 | $221.71 - $235.19 | $370,739 |
2024-06-24 | ALNYLAM PHARMACEUTICALS, INC. | Poulton Jeffrey V.
(EVP, Chief Financial Officer) |
A | Common Stock | A | 3278 | $0.00 - $0.00 | $0 |
2024-06-25 | ALNYLAM PHARMACEUTICALS, INC. | Tanguler Tolga
(EVP, Chief Commercial Officer) |
S | Common Stock | D | 1605 | $221.71 - $235.19 | $370,739 |
2024-06-24 | ALNYLAM PHARMACEUTICALS, INC. | Tanguler Tolga
(EVP, Chief Commercial Officer) |
A | Common Stock | A | 3278 | $0.00 - $0.00 | $0 |
2024-06-25 | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin ...
(CSO & EVP, Head of Research) |
S | Common Stock | D | 1198 | $221.71 - $235.19 | $276,724 |
2024-06-24 | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin ...
(CSO & EVP, Head of Research) |
A | Common Stock | A | 2498 | $0.00 - $0.00 | $0 |
2024-05-29 | ALNYLAM PHARMACEUTICALS, INC. | SCHULMAN AMY W
(Director) |
S | Common Stock | D | 21700 | $148.21 - $149.76 | $3,224,544 |
2024-05-29 | ALNYLAM PHARMACEUTICALS, INC. | SCHULMAN AMY W
(Director) |
M | Common Stock | A | 30000 | $66.83 - $66.83 | $2,004,900 |
A | Grant, award or other acquisition |
C | Conversion of Derivative or Security |
D | Disposition to the issuer of issuer equity securities |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability |
G | Bona fide Gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary Transaction |
J | Other acquisition or disposition |
K | Transaction in equity swap or instrument with similar characteristics |
L | Small Acquisition |
M | Exercise or conversion of derivative security |
O | Exercise of out-of-the-money derivative security |
P | Open Market Purchase |
S | Open Market Sale |
U | Disposition pursuant to a tender of shares in a change of control transaction |
V | Transaction Voluntarily Reported |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |